Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.62 |
| ▸ | MEN1 | O00255 | 3/20 | 0.62 |
| ▸ | POLB | P06746 | 3/20 | 0.62 |
| ▸ | HPGD | P15428 | 3/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.58 |
| ▸ | MAPT | P10636 | 5/20 | 0.58 |
| ▸ | RAB9A | P51151 | 5/20 | 0.58 |
| ▸ | LMNA | P02545 | 4/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 4/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 4/20 | 0.53 |
| ▸ | GFER | P55789 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6281721 | 0.84 | ALDH1A1 (0.62) | KMT2AMEN1POLBHPGDALDH1A1 | |
| SCHEMBL7392988 | 0.84 | TDP1 (0.58) | KMT2AMEN1POLBHPGDCYP1A2 | |
| SCHEMBL4898270 | 0.83 | RAB9A (0.59) | KMT2AMEN1HPGDALDH1A1MAPT | |
| SCHEMBL2958453 | 0.83 | LMNA (0.64) | KMT2AMEN1POLBHPGDCYP1A2 | |
| SCHEMBL69791 | 0.82 | HTT (0.69) | KMT2AMEN1POLBHPGDCYP1A2 | |
| SCHEMBL31571746 | 0.81 | HDAC4 (0.56) | KMT2AMEN1HPGDGAACYP2C9 | |
| SCHEMBL5371049 | 0.80 | KMT2A (0.49) | KMT2AMEN1POLBHPGDCYP1A2 | |
| SCHEMBL2852069 | 0.79 | ALDH1A1 (0.56) | KMT2AMEN1POLBHPGDALDH1A1 | |
| SCHEMBL1660549 | 0.79 | HTT (0.60) | KMT2AMEN1POLBHPGDCYP1A2 | |
| Ethylene SCHEMBL22615238 | 0.78 | HTT (0.64) | KMT2AMEN1POLBHPGDCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119930868-A | Catalyst component containing furoic acid ester compound, preparation method thereof, olefin polymerization catalyst, olefin polymerization method and olefin polymer | 中国石油化工股份有限公司 | 2025-05-06 | — | — | CN | claimed |
| US-8080567-B2 | EP2 receptor agonists | ASTERAND UK LIMITED (GB) | 2011-12-20 | — | — | US | disclosed |
| US-8080567-B2 | EP2 receptor agonists | ASTERAND UK LIMITED (GB) | 2011-12-20 | — | — | US | disclosed |
| US-8080567-B2 | EP2 receptor agonists | ASTERAND UK LIMITED (GB) | 2011-12-20 | — | — | US | disclosed |
| US-7754751-B2 | Preferential inhibition of release of pro-inflammatory cytokines | YUNG SHIN PHARMACEUTICAL IND. CO., LTD. (TW) | 2010-07-13 | — | — | US | disclosed |
| US-20100130556-A1 | EP2 RECEPTOR AGONISTS | ASTERAND UK LIMITED (GB) | 2010-05-27 | — | — | US | disclosed |
| US-20100130556-A1 | EP2 RECEPTOR AGONISTS | ASTERAND UK LIMITED (GB) | 2010-05-27 | — | — | US | disclosed |
| US-20100130556-A1 | EP2 RECEPTOR AGONISTS | ASTERAND UK LIMITED (GB) | 2010-05-27 | — | — | US | disclosed |
| EP-1951701-A2 | EP2 RECEPTOR AGONISTS | ASTERAND UK LIMITED (GB) | 2008-08-06 | — | — | EP | disclosed |
| US-7378532-B2 | Fused pyrazolyl compound | YUNG SHIN PHARMACEUTICAL IND. CO., LTD. (TW) | 2008-05-27 | — | — | US | disclosed |
| CN-1215060-C | Fused pyrazolyl compounds, compositions containing the same, and uses of the compounds | YONGXIN MEDICINE INDUSTRY CO L (CN) | 2005-08-17 | — | — | CN | disclosed |
| US-6387942-B2 | PYRAZOLYL COMPOUND; ANTICOAGULANTS, ANTIPROLIFERATIVE AGENT | YUNG SHIN PHARMACEUTICAL IND. CO. LTD (TW) | 2002-05-14 | — | — | US | disclosed |
| CN-1331076-A | Fused pyrazolyl compounds, compositions containing the same, and uses of the compounds | YONGXIN MEDICINE INDUSTRY CO L (CN) | 2002-01-16 | — | — | CN | disclosed |
| US-20020004518-A1 | Method of treating disorders related to protease-activated receptors-induced cell activation | YUNG SHIN PHARMACEUTICAL IND. CO., LTD. (TW) | 2002-01-10 | — | — | US | disclosed |
| EP-1166785-A1 | Use of pyrazole derivatives for inhibiting thrombin-induced platelet aggregation | Yung Shin Pharmeutical Ind. Co., Ltd. (TW) | 2002-01-02 | — | — | EP | disclosed |
| EP-0667345-B1 | 1-Benzyl-3-(substituted aryl)-condensed pyrazole derivatives as inhibitors of platelet aggregation | YUNG SHIN PHARM IND CO LTD (TW) | 1999-09-29 | — | — | EP | disclosed |
| CN-1039536-C | 1, 3-substituted condensed pyrazole compound and application and preparation method thereof | YONGXIN PHARMACEUTICAL INDUSTR (CN) | 1998-08-19 | — | — | CN | disclosed |
| US-5574168-A | ANTICOAGULANTS | YUNG SHIN PHARM. IND. CO., LTD. (TW) | 1996-11-12 | — | — | US | disclosed |
| CN-1112926-A | 1, 3-substituted condensed pyrazole compound and application and preparation method thereof | YONGXIN PHARMACEUTICAL INDUSTR (CN) | 1995-12-06 | — | — | CN | disclosed |
| EP-0667345-A1 | 1-Benzyl-3-(substituted aryl)-condensed pyrazole derivatives as inhibitors of platelet aggregation | Yung Shin Pharm. Ind. Co. Ltd. (TW) | 1995-08-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130556-A1 | EP2 RECEPTOR AGONISTS | PTGER3, PTGER2, CNR2 | KMT2A 2546/4885MEN1 4201/4885POLB 3892/4885 |
| US-20020004518-A1 | Method of treating disorders related to protease-activated receptors-induced cell activation | F2R, HPN, F2RL1 | KMT2A 3681/4885MEN1 4244/4885POLB 4239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.